<VariationArchive VariationID="192299" VariationName="NM_000091.5(COL4A3):c.40_63del (p.Leu14_Leu21del)" VariationType="Deletion" Accession="VCV000192299" Version="24" RecordType="classified" NumberOfSubmissions="8" NumberOfSubmitters="8" DateLastUpdated="2024-06-23" DateCreated="2019-02-04" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="190092" VariationID="192299">
      <GeneList>
        <Gene Symbol="COL4A3" FullName="collagen type IV alpha 3 chain" GeneID="1285" HGNC_ID="HGNC:2204" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>2q36.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227164624" stop="227314792" display_start="227164624" display_stop="227314792" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="228029280" stop="228179507" display_start="228029280" display_stop="228179507" Strand="+" />
          </Location>
          <OMIM>120070</OMIM>
        </Gene>
        <Gene Symbol="LOC129935730" FullName="ATAC-STARR-seq lymphoblastoid silent region 12397" GeneID="129935730" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>2q36.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227164678" stop="227164857" display_start="227164678" display_stop="227164857" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000091.5(COL4A3):c.40_63del (p.Leu14_Leu21del)</Name>
      <CanonicalSPDI>NC_000002.12:227164755:GGTGCTCCTGCTGCCGCTCCTGCTGGTGCTCCTG:GGTGCTCCTG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2q36.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227164756" stop="227164779" display_start="227164756" display_stop="227164779" variantLength="24" positionVCF="227164755" referenceAlleleVCF="AGGTGCTCCTGCTGCCGCTCCTGCT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="228029472" stop="228029495" display_start="228029472" display_stop="228029495" variantLength="24" positionVCF="228029471" referenceAlleleVCF="AGGTGCTCCTGCTGCCGCTCCTGCT" alternateAlleleVCF="A" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.228029482_228029505del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.228029482_228029505del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.227164766_227164789del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.227164766_227164789del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011591.1" sequenceAccession="NG_011591" sequenceVersion="1" change="g.5202_5225del">
            <Expression>NG_011591.1:g.5202_5225del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011592.1" sequenceAccession="NG_011592" sequenceVersion="1" change="g.4781_4804del">
            <Expression>NG_011592.1:g.4781_4804del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000091.5" sequenceAccession="NM_000091" sequenceVersion="5" change="c.40_63del" MANESelect="true">
            <Expression>NM_000091.5:c.40_63del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000082.2" sequenceAccession="NP_000082" sequenceVersion="2" change="p.Leu14_Leu21del">
            <Expression>NP_000082.2:p.Leu14_Leu21del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_230" sequenceAccession="LRG_230">
            <Expression>LRG_230:g.5202_5225del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_231" sequenceAccession="LRG_231">
            <Expression>LRG_231:g.4781_4804del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000091.4" sequenceAccession="NM_000091" sequenceVersion="4" change="c.40_63delCTGCCGCTCCTGCTGGTGCTCCTG">
            <Expression>NM_000091.4:c.40_63delCTGCCGCTCCTGCTGGTGCTCCTG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_230t1" sequenceAccession="LRG_230t1">
            <Expression>LRG_230t1:c.40_63del24</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="120070.0011" DB="OMIM" />
        <XRef Type="rs" ID="876657397" DB="dbSNP" />
        <XRef ID="CA2145887" DB="ClinGen" />
        <XRef ID="GTR000604058" DB="Genetic Testing Registry (GTR)" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000091.5(COL4A3):c.40_63del (p.Leu14_Leu21del) AND Autosomal recessive Alport syndrome" Accession="RCV000172875" Version="7">
        <ClassifiedConditionList TraitSetID="5721">
          <ClassifiedCondition DB="MedGen" ID="C4746745">Autosomal recessive Alport syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-01-03" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000091.5(COL4A3):c.40_63del (p.Leu14_Leu21del) AND not provided" Accession="RCV000807286" Version="11">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-11-02" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000091.5(COL4A3):c.40_63del (p.Leu14_Leu21del) AND Alport syndrome" Accession="RCV001272220" Version="2">
        <ClassifiedConditionList TraitSetID="6750">
          <ClassifiedCondition DB="MedGen" ID="C1567741">Alport syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2020-09-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000091.5(COL4A3):c.40_63del (p.Leu14_Leu21del) AND multiple conditions" Accession="RCV001535917" Version="4">
        <ClassifiedConditionList TraitSetID="13181">
          <ClassifiedCondition DB="MedGen" ID="C5882663">Autosomal dominant Alport syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4746745">Autosomal recessive Alport syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0241908">Benign familial hematuria</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-02-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000091.5(COL4A3):c.40_63del (p.Leu14_Leu21del) AND COL4A3-related disorder" Accession="RCV003407638" Version="4">
        <ClassifiedConditionList TraitSetID="89121">
          <ClassifiedCondition>COL4A3-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-11-02" NumberOfSubmissions="8" NumberOfSubmitters="8" DateCreated="2019-02-04" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">22887978</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23927549</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24633401</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28570636</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="89121" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="69897" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">COL4A3-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">COL4A3-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">COL4A3-Related Disorders</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13181" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="158" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Autosomal dominant Alport syndrome</ElementValue>
                <XRef ID="MONDO:0007086" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alport syndrome dominant type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Renal failure and sensorineural hearing loss</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ALPORT SYNDROME 3A, AUTOSOMAL DOMINANT</ElementValue>
                <XRef Type="MIM" ID="104200" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alport syndrome 3, autosomal dominant</ElementValue>
                <XRef ID="Alport+Syndrome+Dominant+Type/336" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ATS3A</ElementValue>
                <XRef Type="MIM" ID="104200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare.</Attribute>
                <XRef ID="NBK1207" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="624" />
                <XRef ID="624" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301386</ID>
                <ID Source="BookShelf">NBK1207</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">22166944</ID>
              </Citation>
              <XRef ID="63" DB="Orphanet" />
              <XRef ID="88918" DB="Orphanet" />
              <XRef ID="C5882663" DB="MedGen" />
              <XRef ID="MONDO:0007086" DB="MONDO" />
              <XRef Type="MIM" ID="104200" DB="OMIM" />
            </Trait>
            <Trait ID="282" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Autosomal recessive Alport syndrome</ElementValue>
                <XRef ID="MONDO:0008762" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alport syndrome recessive type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nephropathy and deafness</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ALPORT SYNDROME 2, AUTOSOMAL RECESSIVE</ElementValue>
                <XRef Type="MIM" ID="203780" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0011" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0005" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">COL4A4 Alport Syndrome and Thin Basement Membrane Nephropathy</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ATS2</ElementValue>
                <XRef Type="MIM" ID="203780" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">COL4A3-Related Nephropathy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare.</Attribute>
                <XRef ID="NBK1207" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">COL4A4-Related Nephropathy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="625" />
                <XRef ID="625" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301386</ID>
                <ID Source="BookShelf">NBK1207</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">22166944</ID>
              </Citation>
              <XRef ID="63" DB="Orphanet" />
              <XRef ID="88919" DB="Orphanet" />
              <XRef ID="C4746745" DB="MedGen" />
              <XRef ID="MONDO:0008762" DB="MONDO" />
              <XRef Type="MIM" ID="203780" DB="OMIM" />
            </Trait>
            <Trait ID="2022" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Benign familial hematuria</ElementValue>
                <XRef ID="Benign+Familial+Hematuria/794" DB="Genetic Alliance" />
                <XRef ID="236421001" DB="SNOMED CT" />
              </Name>
              <XRef ID="C0241908" DB="MedGen" />
              <XRef ID="MONDO:0957317" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS141200" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="5721" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="282" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Autosomal recessive Alport syndrome</ElementValue>
                <XRef ID="MONDO:0008762" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alport syndrome recessive type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nephropathy and deafness</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ALPORT SYNDROME 2, AUTOSOMAL RECESSIVE</ElementValue>
                <XRef Type="MIM" ID="203780" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0011" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120070.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="120131.0005" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">COL4A4 Alport Syndrome and Thin Basement Membrane Nephropathy</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ATS2</ElementValue>
                <XRef Type="MIM" ID="203780" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">COL4A3-Related Nephropathy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare.</Attribute>
                <XRef ID="NBK1207" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">COL4A4-Related Nephropathy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="625" />
                <XRef ID="625" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301386</ID>
                <ID Source="BookShelf">NBK1207</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">22166944</ID>
              </Citation>
              <XRef ID="63" DB="Orphanet" />
              <XRef ID="88919" DB="Orphanet" />
              <XRef ID="C4746745" DB="MedGen" />
              <XRef ID="MONDO:0008762" DB="MONDO" />
              <XRef Type="MIM" ID="203780" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6750" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="13255" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Alport syndrome</ElementValue>
                <XRef ID="MONDO:0018965" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS301050" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemorrhagic familial nephritis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemorrhagic hereditary nephritis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Congenital hereditary hematuria</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5785" />
                <XRef ID="5785" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="63" DB="Orphanet" />
              <XRef ID="C1567741" DB="MedGen" />
              <XRef ID="MONDO:0018965" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS301050" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="412101" SubmissionDate="2019-01-31" DateLastUpdated="2019-02-04" DateCreated="2015-06-15">
        <ClinVarSubmissionID localKey="120070.0011_ALPORT SYNDROME 2, AUTOSOMAL RECESSIVE" title="COL4A3, 24-BP DEL, NT40_ALPORT SYNDROME 2, AUTOSOMAL RECESSIVE" />
        <ClinVarAccession Accession="SCV000223865" DateUpdated="2019-02-04" DateCreated="2015-06-15" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-08-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 3 sisters, born of unrelated parents of Ashkenazi Jewish descent, with autosomal recessive Alport syndrome (ATS2; 203780), Webb et al. (2014) identified a homozygous 24-bp deletion (c.40_63del, NM_000091.4) in the COL4A3 gene, resulting in an in-frame deletion of 8 amino acids. The mutation, which was found by linkage analysis followed by candidate gene sequencing, segregated with the disorder in the family. Population analysis yielded a carrier frequency of 0.55% among Ashkenazi Jewish individuals, and haplotype analysis indicated a founder effect. Functional studies of the variant were not performed, but the parents were unaffected, suggesting that heterozygosity for this mutation does not predispose to disease.</Attribute>
              <Citation>
                <ID Source="PubMed">23927549</ID>
              </Citation>
              <XRef DB="OMIM" ID="203780" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A3" />
          </GeneList>
          <Name>COL4A3, 24-BP DEL, NT40</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">24-BP DEL, NT40</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="120070.0011" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">ALPORT SYNDROME 2, AUTOSOMAL RECESSIVE</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2869267" SubmissionDate="2020-12-28" DateLastUpdated="2021-01-02" DateCreated="2021-01-02">
        <ClinVarSubmissionID localKey="NM_000091.4:c.40_63delCTGCCGCTCCTGCTGGTGCTCCTG|Alport syndrome" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001453992" DateUpdated="2021-01-02" DateCreated="2021-01-02" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000091.4:c.40_63delCTGCCGCTCCTGCTGGTGCTCCTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Alport syndrome</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8808661</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3554510" SubmissionDate="2022-02-09" DateLastUpdated="2023-03-04" DateCreated="2021-09-08">
        <ClinVarSubmissionID localKey="GDXSV:221035" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV001815037" DateUpdated="2023-03-04" DateCreated="2021-09-08" Type="SCV" Version="3" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Published with a carrier frequency within the Ashkenazi Jewish population of 1 in 183, and may be a founder variant for Alport syndrome in this population (Webb et al., 2014); Published in vitro studies demonstrate that the deletion alters the COL4A3 signal peptide and changes the subcellular protein localization; variant results in diffuse localization in the cytoplasm and nucleus (Chiereghin et al., 2017); In-frame deletion of 8 amino acids in a non-repeat region; This variant is associated with the following publications: (PMID: 33772369, 12028435, 14582039, 22887978, 23927549, 28570636, 24633401, 29801666)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A3" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:1887440</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000091.4:c.40_63del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_27_20210820101303</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_87_20220209054204</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1841380" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4749991|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000947331" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23927549</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28570636</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28570636</ID>
          </Citation>
          <Comment>This variant, c.40_63del, results in the deletion of 8 amino acid(s) of the COL4A3 protein (p.Leu14_Leu21del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs774798108, gnomAD 0.1%). This variant has been observed in individuals with Alport syndrome (PMID: 23927549, 28570636). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 192299). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects COL4A3 function (PMID: 28570636). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.228029472_228029495del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1795866" SubmissionDate="2019-09-24" DateLastUpdated="2019-11-08" DateCreated="2019-06-02">
        <ClinVarSubmissionID localKey="NM_000091.4:c.40_63del24|MedGen:C4746745" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000919245" DateUpdated="2019-11-08" DateCreated="2019-06-02" Type="SCV" Version="2" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22887978</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24633401</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23927549</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28570636</ID>
          </Citation>
          <Comment>Variant summary: COL4A3 c.40_63del24 (p.Leu14_Leu21del) results in an in-frame deletion that is predicted to remove eight amino acids from the COL4A3 signal peptide sequence of the encoded protein. The variant allele was found at a frequency of 0.00022 in 125078 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in COL4A3 causing autosomal recessive Alport Syndrome (0.00022 vs 0.002), allowing no conclusion about variant significance. c.40_63del24 has been reported in the literature in multiple individuals affected with autosomal recessive Alport Syndrome worldwide (Zhang_2012, Oka_2014, Webb_2014, Chiereghin_2017). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in a disruption of COL4A3 signal peptide, possibly altering protein secretion (Chiereghin_2017). No other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000091.4:c.40_63del24</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Alport syndrome, autosomal recessive</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C4746745" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6341163</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4032664" SubmissionDate="2022-01-11" DateLastUpdated="2022-01-15" DateCreated="2022-01-15">
        <ClinVarSubmissionID localKey="2-228029471-AGGTGCTCCTGCTGCCGCTCCTGCT-A" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002059031" DateUpdated="2022-01-15" DateCreated="2022-01-15" Type="SCV" Version="1" SubmitterName="3billion" OrgID="507830" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <CitationText>PMID:28570636</CitationText>
          </Citation>
          <Citation>
            <CitationText>PMID:22887978</CitationText>
          </Citation>
          <Citation>
            <CitationText>PMID:23927549</CitationText>
          </Citation>
          <Comment>This inframe deletion in the non-repeat region can change the length of the protein and disrupt protein function (PM4_M). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals(PMID: 28570636, 23927549, 22887978, PM3_S). Functional studies provide moderate evidence of the variant having a damaging effect on the gene or gene product(PMID: 28570636, PS3_M). The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000192299).It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000140, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Proband>yes</Proband>
            </Sample>
            <Method>
              <NamePlatform>NovaSeq</NamePlatform>
              <TypePlatform>whole exome sequencing</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0000093" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000091.4:c.40_63del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="203780" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10918354</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3448041" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2021-07-18">
        <ClinVarSubmissionID localKey="NM_000091.5:c.40_63del|OMIM:104200;141200;203780" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001752565" DateUpdated="2022-12-31" DateCreated="2021-07-18" Type="SCV" Version="2" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000091.5:c.40_63del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="104200" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="141200" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="203780" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
          <SubmissionName>SUB9977930</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7696714" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="2538792|COL4A3-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004116011" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The COL4A3 c.40_63del24 variant is predicted to result in an in-frame deletion (p.Leu14_Leu21del). This variant has been reported to be pathogenic for Alport syndrome (AS) (in the homozygous state), and microhematuria/mild proteinuria (in the heterozygous state) (Webb et al. 2014. PubMed ID: 23927549; Longo et al. 2002. PubMed ID: 12028435; Chiereghin et al. 2017. PubMed ID: 28570636). In particular, this deletion was reported to be a pathogenic founder variant in the Ashkenazi Jewish population. This variant is reported in 0.13% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-228029471-AGGTGCTCCTGCTGCCGCTCCTGCT-A). This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000091.4:c.40_63del24</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">COL4A3-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3448041" TraitType="Disease" MappingType="XRef" MappingValue="141200" MappingRef="OMIM">
        <MedGen CUI="CN376803" Name="Hematuria, benign familial, 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448041" TraitType="Disease" MappingType="XRef" MappingValue="104200" MappingRef="OMIM">
        <MedGen CUI="C5882663" Name="Autosomal dominant Alport syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1795866" TraitType="Disease" MappingType="Name" MappingValue="Alport syndrome, autosomal recessive" MappingRef="Preferred">
        <MedGen CUI="C4746745" Name="Autosomal recessive Alport syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3554510" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="412101" TraitType="Disease" MappingType="Name" MappingValue="ALPORT SYNDROME 2, AUTOSOMAL RECESSIVE" MappingRef="Preferred">
        <MedGen CUI="C4746745" Name="Autosomal recessive Alport syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4032664" TraitType="Disease" MappingType="XRef" MappingValue="203780" MappingRef="OMIM">
        <MedGen CUI="C4746745" Name="Autosomal recessive Alport syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7696714" TraitType="Disease" MappingType="Name" MappingValue="COL4A3-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="COL4A3-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1841380" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2869267" TraitType="Disease" MappingType="Name" MappingValue="Alport syndrome" MappingRef="Preferred">
        <MedGen CUI="C1567741" Name="Alport syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4032664" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000093" MappingRef="HP">
        <MedGen CUI="C0033687" Name="Proteinuria" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448041" TraitType="Disease" MappingType="XRef" MappingValue="203780" MappingRef="OMIM">
        <MedGen CUI="C4746745" Name="Autosomal recessive Alport syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

